From industry leading sequencing platforms, to world-class microarray systems and informatic solutions, Illumina offers workflows that fit the complex needs of researchers across the genomic spectrum. Ranging from single-cell and whole-genome sequencing to population-scale genomics, come learn how Illumina can partner with you in advancing the future of genomics. Visit us at our booth to learn more about our solutions and attend our featured talks.
Industry Ed Workshop
The power of Multiomics: Discoveries in Genetic, Complex, and Infectious Disease Research
Launches Tuesday, October 18th at 2:30 PM
Multiomics provides an integrated perspective to power discovery across multiple levels of biology. These biological analysis approaches combine data across multiple modalities including genomics, transcriptomics, epigenetics, and proteomics. When used together, one can measure and understand changes in genetic variation, gene expression, regulation, protein expression and the interactions of these various modalities.
In this session, hear Dr. Kathleen Barnes, Professor of Medicine and Epidemiology and Director of the Colorado Center for Personalized Medicine (CCPM), share her team’s multiomic approaches to studying host response to SARS-CoV-2 infection.
You will also hear from Illumina’s Vice President of Product Integration and Customer Collaboration, Dr. Ashley Van Zeeland on how Illumina’s sequencing, array and informatics solutions can support your multiomic research studies.
Dr. Kathleen Barnes
Professor of Medicine and Epidemiology and Director of the Colorado Center for Personalized Medicine (CCPM)
University of Colorado
Dr. Ashley Van Zeeland
Vice President of Product Integration and Customer Collaboration
Advancements in translational biomarker identification from cell-free RNA
On-Demand from start of show
Liquid biopsy is most often associated with cell-free DNA, but new research has shown additional value in interrogating a broader diversity of analytes in the blood. Cell-free RNA (cfRNA) is one such molecule that has been shown to reflect dynamic changes in many tissues. Researchers at Illumina have optimized key variables to enable scalable, end-to-end workflow solutions for whole-transcriptome library preparations of cfRNA. This assay was subsequently used to detect a molecular signature in early-onset preeclampsia patients which could accurately classify subjects across independent cohorts and reflected a broad range of biological processes known to be affected by this disease. Continued application of cfRNA stands to benefit a multitude of human health concerns by empowering non-invasive interrogations of disease etiology and identification of predictive, diagnostic, and prognostic biomarkers, all of which will further facilitate our transition into the era of personalized medicine.
Dr. Suzanne Rohrback
Integrating Polygenic Risk Scores into Research and Clinical Settings
On-Demand from start of show
Genetic tests to determine risk for monogenic diseases that are caused by a single mutation have been in use for over a decade. However, determining risk for complex diseases, which can be caused by hundreds to thousands of genetic variants that act in conjunction with environmental factors, remains challenging. Enter polygenic risk scoring.
Polygenic risk scores represent the total number of genetic variants that an individual has to assess their heritable risk of developing a particular disease. Polygenic risk scores have the potential to impact complex disease research and healthcare by assessing an individual's risk of disease, analyzing populations based on disease risk, and selecting samples within cohorts for further analysis.
Join us in this session as we hear from Dr. Giordano Bottà and Dr. George Busby of Allelica and Dr. Mehdi Keddache of Illumina as they explore polygenic risk scoring, how it works and how it integrates into research and clinical settings.
Dr. Giordano Bottà
Dr. George Busby
CSO & Co-Founder
Senior Sales Specialist